This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Crescendo Biologics Announces The Crescendo Mouse

CAMBRIDGE, England, January 16, 2013 /PRNewswire/ --

Breakthrough technology generates superior human single domain antibody V H   fragments in a transgenic mouse

Crescendo Biologics Limited (Crescendo) today announces the Crescendo Mouse, a breakthrough in antibody fragment technology which allows the efficient generation of high-quality fully human single domain antibody V H fragments from a transgenic mouse.

V H fragments are next-generation antibody-based therapeutic proteins that have exciting applications beyond the scope of full length antibodies. They are the smallest antibody fragments that retain the ability to bind antigens specifically and with high affinity and, when generated in the Crescendo Mouse, human V H have superior biophysical properties that make them highly attractive drug products. V H fragments can be formulated for topical delivery, are highly amenable to modular engineering of bispecific and multivalent products, have superior tissue penetration characteristics, and are simple to manufacture in microbial systems.

Mike Romanos, CEO of Crescendo, said, "The majority of recent approvals for monoclonal antibody therapeutics have been fully human and derived from transgenic mice. Transgenic mice are highly valued for their ability to generate fully human antibodies that develop in vivo, through the natural process of B cell maturation, and require little or no further manipulation to create highly potent therapeutics.  The Crescendo Mouse combines all the benefits of transgenic mouse technology with the excellent drug qualities of single domain V H fragments. We believe this will enable rapid generation of superior therapeutic products, and fully realise the potential of human V H fragments in the development of our pipeline and that of future partners."

Key to generation of V H fragments in the mouse is Crescendo's proprietary triple knock out (TKO) background, which is completely devoid of all endogenous immunoglobulin chains, and therefore enables in vivo maturation of human V H single domains uncontaminated by association with any light chains. B cell development within the Crescendo Mouse is driven from a construct introduced into the TKO background that combines human V- D- and J- genes, together with murine constant and regulatory regions, to generate heavy chain only antibodies. The power of the mouse immune system is consequently fully harnessed to drive B cell development and maturation, leading to a diverse repertoire of fully-human V H domains with superior stability and solubility.

The Crescendo Mouse responds robustly to immunisation with target proteins and in vivo B cell maturation yields diverse human V H domains, from all V H families, which have also undergone somatic hypermutation. Because the antibody response following immunisation is entirely encompassed within the V H domain, Crescendo has been able to develop a fully integrated discovery process utilising in vitro display to comprehensively mine and rapidly identify V H drug candidates directly from immunised mice. Purified V H fragments have been shown to bind immunogen with high affinity, exhibit very high thermostability and have excellent expression levels. These data indicate that B cell maturation in the Crescendo Mouse is driving selection and optimisation of matured human V Hdomains, with all of the properties that make them highly potent, drug quality antibody-based therapeutics.

Crescendo has commenced discovery for its own pipeline of therapeutic products, and is in discussion with pharmaceutical companies interested in accessing the Crescendo Mouse.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs